Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis
Under a Creative Commons license
open access
Highlights
► JIA pathogenesis involves dysregulation of both adaptive and innate immunity. ► Drugs interacting with TNFα and IL-1β are increasingly being used in JIA treatment. ► An evidence-based multidisciplinary consensus was created. ► Evidence and consensus-based guidelines may be a useful tool to standardize JIA care.
Abbreviations
ACR
American College of Rheumatology
AE
adverse events
AGREE
appraisal of guidelines for research and evaluation
AWMF
Association of the Scientific Medical Associations
Bw
bodyweight
CAPS
cryopyrin-associated periodic syndromes
CD
cluster of differentiation
CIOMS
Council for International Organizations of Medical Sciences
CTLA-4
cytotoxic T-lymphocyte antigen 4
DELBI
German instrument for methodological guideline appraisal
DMARDs
disease modifying anti-rheumatic drugs
EBM
evidence based medicine
EMA
European Medical Agency
EULAR
European League against Rheumatism
FDA
Food and Drug Administration
GC
glucocorticoids
GKJR
German Society for Pediatric Rheumatology
GPs
general practitioners
IgG
immunoglobulin G
IL
interleukin
ILAR
International League of Associations for Rheumatology
JDM
juvenile dermatomyositis
JIA
juvenile idiopathic arthritis
MAS
macrophage activation syndrome
Max
maximum
MTX
methotrexate
NGT
nominal group technique
NSAID
nonsteroidal anti-inflammatory drug(s)
SCT
stem cell transplantation
SLE
systemic lupus erythematodes
SoJIA
systemic onset of juvenile idiopathic arthritis
TNF
tumor necrosis factor
TPMT
thiopurinmethyltransferase
Keywords
Juvenile idiopathic arthritis
Treatment
Guideline
Consensus
Children and adolescents
Cited by (0)
- 1
Contributed equally.
Copyright © 2011 Elsevier Inc.